The first experimental evidence pointing at a role for RNASET2 in tumor suppression came from a study on human ovarian carcinoma, which showed a marked downregulation of this gene’s expression in a panel of ovarian cancer cell lines and primary tumors, coupled with the ability of RNASET2 to inhibit tumor growth in vivo when overexpressed in several cancer cell lines following their inoculation in xenograft mouse models (Figure 1E) [95]. This evidence concerns the gene RNASET2 and neoplasm.